All relevant data are within the paper and its Supporting Information file. All genomes are available from the NCBI database under bio-project accession number PRJNA431326.

Introduction {#sec001}
============

*Pseudomonas aeruginosa* infections can be severe in people with a compromised immune system and impaired anatomical structures caused by, for example burns, cystic fibrosis or mechanical abrasions \[[@pone.0204936.ref001]\]. *P*. *aeruginosa* is a successful opportunistic pathogen in part due to its production of a diverse repertoire of pathogenic factors and its innate ability to evade the host immune system \[[@pone.0204936.ref002]\]. Treatment of *P*. *aeruginosa* infections can be challenging due to the inherent antibiotic resistance, where some studies have shown that half of the isolates from clinical infections were resistant to antibiotics \[[@pone.0204936.ref003]\]. Furthermore, reports on co-selection of antibiotic resistance and pathogenic factors indicate that antibiotic resistance may be a factor for the evolution of more virulent strains of *P*. *aeruginosa* or *vice versa* \[[@pone.0204936.ref004]--[@pone.0204936.ref013]\].

Many Gram-negative bacteria, including *P*. *aeruginosa*, possess type III secretion systems (TTSS), which they utilise to introduce virulence factors directly into host cells \[[@pone.0204936.ref014]\]. In *P*. *aeruginosa*, TTSS transports four secreted factors: ExoU, ExoS, ExoY and ExoT. However, all of these factors may not be common in all *P*. *aeruginosa* strains. For example, the *exoS* gene was present in 58--72%, the *exoU* gene in 28--42%, the *exoY* gene in 89% and the *exoT* gene in 92--100% of isolates from acute infections \[[@pone.0204936.ref015]\]. Pathogenic strains contain either *exoU* or *exoS*, but rarely both \[[@pone.0204936.ref016], [@pone.0204936.ref017]\]. The *exoU* gene is associated with a genomic island and its acquisition may cause loss of the *exoS* \[[@pone.0204936.ref018], [@pone.0204936.ref019]\]. The *exoU* gene encodes a cytotoxic protein that rapidly destroys the cell membranes of mammalian cells by its phospholipase activity \[[@pone.0204936.ref019]\]. The presence of *exoU* correlates with phenotypes that are responsible for the severe outcome of many infections including pneumonia \[[@pone.0204936.ref020]\] and keratitis \[[@pone.0204936.ref021]\]. Up to two-thirds of ocular isolates of *P*. *aeruginosa* possess the *exoU* gene \[[@pone.0204936.ref022]\], which is a much higher rate than the isolates from other infections \[[@pone.0204936.ref006], [@pone.0204936.ref023], [@pone.0204936.ref024]\].

The frequency of antibiotic resistance of the *exoU* gene carrying strains is higher than that of *exoS-*strains; \[[@pone.0204936.ref005], [@pone.0204936.ref010]\] the reason for this higher frequency remains undefined. *P*. *aeruginosa* strains with the *exoU* gene tend to harbour mutations in quinolone resistance determining regions (QRDRs) that lead to fluoroquinolone resistance \[[@pone.0204936.ref005], [@pone.0204936.ref009]\]. Whilst it is known that strains of *P*. *aeruginosa* can possess mutations in resistance determining regions affecting beta-latam susceptibility, such as the chromosomal beta-lactamase gene (*ampC*), its transcriptional regulator (*ampR*) \[[@pone.0204936.ref025]\] and a repressor gene (*mexR*) that negatively regulates expression of an active efflux pump (MexAB-OprM) \[[@pone.0204936.ref026]\], the correlation between the *exoU* carriage and mutations in drug resistance determining regions has not been extensively examined.

We hypothesised that possession of the *exoU* gene correlates with mutations not only in QRDRs but also in beta-lactam resistance determining regions. The aim of this study was to examine the correlation between the virulent genotypes (*exoS* vs. *exoU*) and resistance to beta-lactam and fluoroquinolone antibiotics in *P*. *aeruginosa* strains. Furthermore, we examined the relative expression of specific genes to confirm their role in antibiotic resistance.

Materials and methods {#sec002}
=====================

Bacterial isolates and antibiotic susceptibility testing {#sec003}
--------------------------------------------------------

Twenty-two *P*. *aeruginosa* strains isolated from anterior eye infections, microbial keratitis (MK), or lungs of cystic fibrosis patients from India and Australia were used in this study ([Table 1](#pone.0204936.t001){ref-type="table"}). The minimum inhibitory concentrations (MICs) of ceftazidime (Sigma-Aldrich, Inc., St. Louis, MO, USA), cefepime (European Pharmacopoeia, Strasbourg, France) aztreonam (Sigma-Aldrich, Inc), ticarcillin (Sigma-Aldrich, Inc), imipenem (Sigma-Aldrich, Inc), levofloxacin (Sigma-Aldrich, Inc), ciprofloxacin (Sigma-Aldrich, Inc), and moxifloxacin (European Pharmacopoeia) were determined by the broth microdilution method as described by the Clinical and Laboratory Standards Institute (CLSI) \[[@pone.0204936.ref027]\]. The MIC was taken as the lowest concentration of an antibiotic in which no noticeable growth (turbidity) was observed \[[@pone.0204936.ref028]\] and the break point was established according to published standards \[[@pone.0204936.ref029], [@pone.0204936.ref030]\]. Both resistant and intermediate resistant strains were considered here as resistant.

10.1371/journal.pone.0204936.t001

###### Strains and origin of *Pseudomonas aeruginosa* used in this study.

![](pone.0204936.t001){#pone.0204936.t001g}

  Isolate designation   Origin                                                                           Associated infections
  --------------------- -------------------------------------------------------------------------------- -----------------------
  PA17                  Australia                                                                        MK
  PA149                 Australia                                                                        MK
  PA157                 Australia                                                                        MK
  PA171                 Australia                                                                        MK
  PA175                 Australia                                                                        MK
  PA40                  Australia                                                                        MK
  PA32                  India                                                                            MK
  PA33                  India                                                                            MK
  PA34                  India                                                                            MK
  PA35                  India                                                                            MK
  PA37                  India                                                                            MK
  PA82                  India                                                                            MK
  PA55                  Australia                                                                        CF
  PA57                  Australia                                                                        CF
  PA59                  Australia                                                                        CF
  PA64                  Australia                                                                        CF
  PA66                  Australia                                                                        CF
  PA86                  Australia                                                                        CF
  PA92                  Australia                                                                        CF
  PA100                 Australia                                                                        CF
  PA102                 Australia                                                                        CF
  PAO1                  Reference strain \[[@pone.0204936.ref064]\] (RefSeq accession no. NC_002516.2)   

MK = Microbial keratitis, CF = Cystic fibrosis

DNA extraction and sequencing {#sec004}
-----------------------------

Bacterial DNA was extracted from overnight cultures grown on Trypticase Soy Agar (TSA; Oxoid Ltd., Basingstoke, UK), using the DNeasy Blood and Tissue Kit (Qiagen, Hilden, Germany) following the manufacturer's instructions. The extracted DNA was sequenced on MiSeq (Illumina, San Diego, CA, USA) platform generating 300 bp paired-end reads. The paired-end library was prepared using Nextera XT DNA library preparation kit (Illumina, San Diego, CA, USA). All of the libraries were multiplexed on one MiSeq run. Genome assembly and annotations were performed using SPAdes version 3.11.1 \[[@pone.0204936.ref031]\] and Prokka version 1.7 \[[@pone.0204936.ref032]\]. BLAST search was performed to investigate carriage of *exoU* and *exoS* genes. All nucleotide sequences were deposited in NCBI GenBank data base under Bio-project accession number PRJNA431326.

Sequence analysis and variant calling {#sec005}
-------------------------------------

The mutations in selected resistance genes (*gyrA*, *gryB*, *parC*, *parE*, *mexR*, *ampC*, *ampD* and *ampR*) of each strain were determined with reference to *P*. *aeruginosa* PAO1 (Genbank RefSeq accession no. NC_002516.2). Briefly, the reference genome was mapped to the paired-end reads for each isolate using Bowtie2 version 2.3.2 \[[@pone.0204936.ref033]\] and the variants were compiled and annotated using SAMtools, version 1.7 \[[@pone.0204936.ref034]\] and SnpEff version 4.3 \[[@pone.0204936.ref035]\]. The QRDRs were assigned to amino acid positions 83 to 87 of the GyrA protein, positions 429 to 585 of the GyrB protein, positions 82 to 84 of the ParC protein, and positions 357 to 503 of the ParE protein \[[@pone.0204936.ref036]\]. For *ampC* variants, mutations different from common polymorphisms (G27D, R79Q, T105A, Q156R, L176R, V205L, and G391A), which are present in both susceptible and non-susceptible strains \[[@pone.0204936.ref037]\] were considered here. Mutations in *mexR* or *ampR* were considered as significant for resistance from previous literature \[[@pone.0204936.ref038]--[@pone.0204936.ref040]\].

Total RNA extraction and qRT-PCR analysis {#sec006}
-----------------------------------------

Strains were revived from frozen stocks into 5 mL Trypticase Soy Broth (TSB; Oxoid) and grown to mid-exponential phase (OD~660~ 1.5) and 1 ml was centrifuged at 6000 *g* for 3 min to harvest the cells. The pellet was mixed with 1 mg/ml lysozyme in Tris-EDTA buffer (TE; 10 mM Tris-hydrochloride and 1.0 mM EDTA pH 8.0) to lyse the cells. RNA extraction was performed using the ISOLATE RNA Mini Kit (Bioline, London, UK) following the manufacturer instructions for RNA isolation from bacteria. The RNA extract was treated with DNase1 (Bioline) to eliminate the DNA contamination and purified by ethanol precipitation \[[@pone.0204936.ref041]\]. RNA purity and concentration was measured by NanoDrop spectrophotometer (ND-1000, ThermoFisher, MA, USA). cDNA was synthesized from 1 μg of total RNA using SuperScript First-Strand synthesis system for RT-PCR (Invitrogen, Carlsbad, CA, USA) employing random primers and following the manufacturer's protocol. Quantitative PCR was performed with a PowerUp SYBR Green Master Mix (Applied Biosystems, Austin, TX, USA), using 96 well optical plates (MicroAmp Fast Optical, Applied Biosystems) following the manufacturer's instructions and cycle conditions. A 7500 Fast Real-Time PCR System (Applied Biosystems) was used to measure the expression levels of the target DNA sequences using gene specific primers ([Table 2](#pone.0204936.t002){ref-type="table"}). The relative expression levels were quantified using the comparative C~T~ method \[[@pone.0204936.ref042]\] to obtain the fold change in each gene with reference to the respective genes of *P*. *aeruginosa* PAO1, which does not carry the *exoU* gene. A house keeping gene, *rpsL* encoding the 30S ribosomal protein S12, was used as an internal expression control for normalisation. The experiments were carried out three times in triplicate and the mean and standard deviations were calculated.

10.1371/journal.pone.0204936.t002

###### Primers used in this study.

![](pone.0204936.t002){#pone.0204936.t002g}

  Genes                         Functions                                        Primers (5--3)                Length (bp)   Nucleotide position in gene   Product length (bp)   References
  ----------------------------- ------------------------------------------------ ----------------------------- ------------- ----------------------------- --------------------- ----------------------------
  *ampC*                        Cephalosporinase                                 `CGGCTCGGTGAGCAAGACCTTC`--F   22            264                           218                   \[[@pone.0204936.ref046]\]
  `AGTCGCGGATCTGTGCCTGGTC–R`    22                                               481                                                                                             
  *mexR*                        Transcriptional regulator                        `CGCGAGCTGGAGGGAAGAAACC–F`    22            217                           150                   \[[@pone.0204936.ref046]\]
  `CGGGGCAAACAACTCGTCATGC–R`    22                                               366                                                                                             
  *ampR*                        Transcriptional regulator                        `TGCTGTGTGACTCCTTCGAC–F`      20            215                           160                   This Study
  `AGATCGATGAAGGGATGGCG–R`      20                                               374                                                                                             
  *rpsL*                        30S ribosomal protein S12 (house keeping gene)   `GCAAGCGCATGGTCGACAAGA–F`     21            35                            201                   \[[@pone.0204936.ref046]\]
  `CGCTGTGCTCTTGCAGGTTGTGA–R`   23                                               235                                                                                             

Results {#sec007}
=======

Possession of *exoU/exoS* and antibiotic resistance {#sec008}
---------------------------------------------------

BLAST search showed that of the 22 isolates, 8 out of the 13 eye isolates (62%) possessed the *exoU* gene, while it was absent from the cystic fibrosis (CF) isolates ([Fig 1B](#pone.0204936.g001){ref-type="fig"}). Except for a CF strain (PA57) which lacked both *exoU* and *exoS* genes, all strains that lacked the *exoU* gene carried the *exoS* gene and none of the studied strains harboured both genes. For the *exoS* strains, 8/13 showed a medium level (2--16 μg/ml) of resistance to at least one fluoroquinolone and 8/13 were resistant to at least one beta-lactam, mostly ticarcillin ([Fig 1A](#pone.0204936.g001){ref-type="fig"}). Six of these eight strains were resistant to both a fluoroquinolone and beta-lactam. All except one (PA175) *exoU* strain were resistant to at least two tested fluoroquinolones with MICs of between 2--128 μg/ml with six strains having ≥32 for ciprofloxacin. All the *exoU* strains were resistant to at least three beta-lactams except for PA175, which was only resistant to ticarcillin and imipenem ([Fig 1B, 1C and 1D](#pone.0204936.g001){ref-type="fig"}).

![Antibiotic susceptibility patterns and possesion of *exoU* and *exoS* genes.\
**A)** Antibiotic susceptibility pattern of *exoU* and *exoS* strains. Both resistant and intermediate resistant strains were considered here as resistant. Black boxes represent resistance and white boxes represent susceptibility. **B)** Number of microbial keratitis (MK) and cystic fibrosis (CF) isolates that carry *exoU* or *exoS* genes. **C)** susceptibility of *exoU* and *exoS* strains to fluoroquinolones. **D)** susceptibility of *exoU* and *exoS* strains and to beta-lactams. \[CIP = ciprofloxacin, LEVO = Levofloxacin, MOX = Moxifloxacin, CFT = ceftazidime, CEF = cefepime, TIC = ticarcillin, IMI = imipenem, AZT = Aztreonam\].](pone.0204936.g001){#pone.0204936.g001}

Mutations in target genes of QRDRs and possession of *exoU* {#sec009}
-----------------------------------------------------------

Mutations in four different QRDRs were examined with reference to *P*. *aeruginosa* PAO1. Of the strains containing *exoU*, 6/8 had a T83I mutation in *gyrA* and 5/8 had combined mutations in both *gyrA* (T83I) and *parC* (S87L); none of the *exoS* strains had either of these mutations. Strains with mutations in *gyrA* or *parC* were resistant to all three fluoroquinolones and these mutations correlated with higher MICs for fluoroquinolones ([Table 3](#pone.0204936.t003){ref-type="table"}). None of the *exoS* strains possessed mutations in *gyrA* and *parC*. However, mutations were observed in *gyrB* and *parE* in five *exoS-*strains which were associated with higher MIC to fluoroquinolones ([Table 3](#pone.0204936.t003){ref-type="table"}). Interestingly, no mutations in *gyrB* or *parE* were found in the *exoU* strains. It should be noted that five strains (PA82, PA17, PA40, PA100 and PA171) had no mutations in any of these genes, but were resistant to at least one fluoroquinolone, although resistance tended to be ≤8 μg/ml, except PA82 which had an MIC of 64 μg/ml for ciprofloxacin.

10.1371/journal.pone.0204936.t003

###### Mutations in the quinolone resistance determining region of *P*. *aeruginosa* and the MIC of fluoroquinolones.

![](pone.0204936.t003){#pone.0204936.t003g}

                     Strain                                        Genes                                            MIC (μg/ml) of Fluoroquinolones                                        
  ------------------ --------------------------------------------- ------------------------------------------------ --------------------------------- ------- --------- -------- --------- --------
  *exoU* strain*s*   PA31                                          T83I                                                                               S87L              **32**   **32**    **64**
  PA32               T83I                                                                                           S87L                                      **64**    **32**   **128**   
  PA33               T83I                                                                                           S87L                                      **128**   **32**   **64**    
  PA34                                                                                                                                                        **2**     2        **8**     
  PA35               T83I                                                                                           S87L                                      **64**    **32**   **128**   
  PA37               T83I                                                                                           S87L                                      **64**    **32**   **128**   
  PA82                                                                                                                                                        **64**    **4**    4         
  PA175              T83I                                                                                                                                     0.25      0.25     1         
  *exoS* strain*s*   PA17                                                                                                                                               **2**    1         **8**
  PA40                                                                                                                                                        **4**     2        2         
  PA55                                                                                                                                                        1         0.5      4         
  PA59                                                                                                                                                        0.125     0.25     1         
  PA64                                                                                                                                                A473V   **8**     **16**   **16**    
  PA66                                                             E468D                                                                                      **2**     **4**    **8**     
  PA86                                                             L457-458A[\*](#t003fn004){ref-type="table-fn"}                                             0.5       1        2         
  PA92                                                             S466F                                                                              A473V   **4**     **4**    **16**    
  PA100                                                                                                                                                       **2**     1        **8**     
  PA102                                                                                                                                               A473V   **2**     **4**    **8**     
  PA149                                                                                                                                                       0.5       0.5      2         
  PA157                                                                                                                                                       0.25      0.5      2         
  PA171                                                                                                                                                       **4**     2        **8**     
                     PAO1[\*\*](#t003fn005){ref-type="table-fn"}                                                                                                        0.25     0.25      1

The numbers denote change in amino acid positions when compared with the genome of *P*. *aeruginosa* PAO1.

**Bold** = resistant or intermediate resistant.

CIP = ciprofloxacin, LEVO = Levofloxacin, MOX = Moxifloxacin.

\*Insertion and frameshift variant.

\*\* Reference strain

Mutations associated with beta-lactam antibiotics and *exoU* {#sec010}
------------------------------------------------------------

This study also examined mutations in cephalosporinase (*ampC*) and its regulator (*ampR*) and the efflux pump MexAB-OprM regulator (*mexR*). A number of mutations were seen in *ampC*, but only those mutations that have been previously reported to be significant contributors to resistance were considered here (all observed mutations are shown in [S1 Table](#pone.0204936.s001){ref-type="supplementary-material"}). Variation in amino acid position V356I was common in six *exoU* strains, Q155R was found in strain PA82 and no significant mutations were observed in PA34. Such mutations were, however absent in *exoS-*strains. Similarly, all of the *exoU* strains had a common mutation in the in *mexR* gene at amino acid position 126, changing valine to glutamic acid, in addition to mutations at A110T in PA34 and K76Q in PA175. Such mutations were not present in the *exoS* strains. Furthermore, all the *exoU* strains had various mutations (E114A, G283E, and M288R) in the *ampR* gene, but only one *exoS* strain (PA171) had mutations in this gene and this at position 244. The susceptibility results showed that possession of such mutations was associated with higher MICs to various beta-lactams, except for strain PA175 which had all these mutations in *mexR*, *ampC*, and *ampR* genes but was sensitive to cefepime and ceftazidime ([Table 4](#pone.0204936.t004){ref-type="table"}).

10.1371/journal.pone.0204936.t004

###### Mutations in beta-lactam resistance determining regions and beta lactam resistance profiles.

![](pone.0204936.t004){#pone.0204936.t004g}

                   Strains                                       Genes   MIC (μg/ml) towards beta-lactams                                                             
  ---------------- --------------------------------------------- ------- ---------------------------------- -------------- ----------- ----------- --------- -------- --------
  *exoU* strains   PA31                                          V126E   V356I                              G283E, M288R   **16**      **16**      **64**    **4**    **16**
  PA32             V126E                                         V356I   G283E, M288R                       **16**         8           **64**      **4**     **32**   
  PA33             V126E                                         V356I   G283E, M288R                       **32**         **16**      **128**     **8**     8        
  PA34             A110T, V126E                                          E114A, G283E, M288R                4              **32**      **\>128**   **16**    8        
  PA35             V126E                                         V356I   G283E, M288R                       **16**         **32**      **128**     **8**     **16**   
  PA37             V126E                                         V356I   G283E, M288R                       **16**         8           **64**      **4**     8        
  PA82             V126E                                         Q155I   G283E                              **\>128**      **\>128**   **32**      1         8        
  PA175            K76Q, V126E                                   V356I   G283E, M288R                       2              4           **64**      **4**     8        
  *exoS* strains   PA17                                                                                                    4           4           **128**   1        8
  PA40                                                                                                      1              2           **64**      **4**     8        
  PA55                                                                                                      **32**         **64**      **32**      **4**     8        
  PA59                                                                                                      2              2           16          1         8        
  PA64                                                                                                      **16**         **64**      **32**      1         4        
  PA66                                                                                                      **16**         **64**      **32**      0.25      8        
  PA86                                                                                                      4              8           **64**      1         8        
  PA92                                                                                                      **32**         **64**      8           1         1        
  PA100                                                                                                     4              8           16          2         0.5      
  PA102                                                                                                     1              1           16          0.5       4        
  PA149                                                                                                     2              4           16          1         4        
  PA157                                                                                                     2              4           16          1         4        
  PA171                                                                  R244W                              2              1           **32**      **4**     8        
                   PAO1[\*\*](#t004fn004){ref-type="table-fn"}                                                             1           1           16        1        4

The numbers denote change in amino acid positions when compared with the genome of *P*. *aeruginosa* PAO1.

Bold = resistance or intermediate resistance.

CFT = ceftazidime, CEF = cefepime, TIC = ticarcillin, IMI = imipenem, AZT = Aztreonam.

\*\*Reference strain

Expression analysis of *ampC*, *ampR* and *mexR* genes {#sec011}
------------------------------------------------------

The relative expression of *ampC*, *ampR* and *mexR* genes in all of the *exoU* strains and three randomly selected *exoS* strains (PA55, PA86 and PA149) were compared to *P*. *aeruginosa* PAO1 to analyse the effect of such mutations on expression ([Fig 2](#pone.0204936.g002){ref-type="fig"}). The relative expression of the *ampC* was two to nine fold higher in all of the *exoU* strains and was slightly lower in all three *exoS* strains compared to PAO1. Similarly, the relative expression of the *ampR* was at least two fold higher for five out of eight *exoU* strains. For an *exoU* strain (PA33), the *ampR* gene was repressed six fold. The expression of *mexR* gene was repressed in six *exoU* strains while overexpression of *mexR* was observed in two *exoS* strains relative to PAO1.

![Expression of cephalosporinase (*ampC*) its regulator (*ampR*) and the efflux pump MexAB-OprM regulator (*mexR*) in strains.\
The relative expression levels were compared to *Pseudomonas aeruginosa* PAO1 (widetype, non-*exoU* strain) and are presented as fold change in gene expression. Error bars represent standard deviation of the mean fold change.](pone.0204936.g002){#pone.0204936.g002}

Discussion {#sec012}
==========

The *exoU* gene is commonly found in *P*. *aeruginosa* strains isolated from contact lens-related microbial keratitis, at frequencies of 46--54%, \[[@pone.0204936.ref011]\] whereas it only occurs in 0--14% of non-ocular isolates \[[@pone.0204936.ref006], [@pone.0204936.ref022]--[@pone.0204936.ref024]\]. Similar to a previous report, \[[@pone.0204936.ref010]\] *exoU*+ strains in the current study had higher resistance to beta-lactams than *exoS*+ strains (100% *exoU* strains vs. 61% *exoS* strains were resistant to at least one beta-lactam). ExoU secreting *P*. *aeruginosa* had more mutations in genes that are associated with beta-lactam resistance (*mexR*, *ampC* and *ampR*) than did *exoS*+ strains. Gene expression analysis suggested that such mutations generally lead to antibiotic resistance, as the expression of *ampC* and *ampR* generally increased while the expression of *mexR* was decreased, compared to the sensitive strain PAO1.

Several *in vivo* and *in vitro* studies have shown that the *exoU* carrying *P*. *aeruginosa* is associated with severe outcome of diseases \[[@pone.0204936.ref007], [@pone.0204936.ref012], [@pone.0204936.ref020], [@pone.0204936.ref021], [@pone.0204936.ref043], [@pone.0204936.ref044]\]. In additions, results of this and other studies confirmed that *exoS*+ and *exoU*+ strains have different antibiotic resistance patterns \[[@pone.0204936.ref010], [@pone.0204936.ref045]\]. Therefore, they may require different treatment strategies. Knowing the virulence gene profiles, the clinical outcome of the patients the resistance patterns might be predicted, and this information could be used in deciding appropriate antibiotic treatment.

A mutation at amino acid position 126 (changing valine to glutamic acid) in MexR was common in all *exoU*+ strains. Underexpression of *mexR* has been associated with antibiotic resistance in *P*. *aeruginosa* \[[@pone.0204936.ref046]\]. Mutations in *mexR* contribute to the over-expression of the MexAB-OprM efflux pump, \[[@pone.0204936.ref047], [@pone.0204936.ref048]\] which in turn is specific to increased resistance to beta-lactams \[[@pone.0204936.ref049]\]. The current study demonstrated that mutation in *mexR* was correlated with lower transcription of this gene in 75% of *exoU*+ strains. The higher expression of *mexR* in *exoS*+ strains observed here appears to support the hypothesis that possession of the *exoU* gene is associated with beta-lactam resistance.

Various different mutations in *ampC* and *ampR* between *exoU* and *exoS* subpopulations were revealed in the current study. Mutations in *ampC* and *ampR* were more common in *exoU*+ strains. Berrazeg *et al* \[[@pone.0204936.ref037]\] demonstrated that mutations in *ampC* at amino acid positions G27D, R79Q, T105A, Q156R, L176R, V205L, and G391A were not correlated with beta-lactam resistance and hence were excluded here from analysis in the current study. Mutations at amino acid positions Q155I and V356I in *ampC* were observed in *exoU*+ strains, and all these strains had increased gene expression of *ampC*, suggesting that these mutations may be responsible for this reduced expression. A few *exoS*+ strains and one *exoU*+ strain (PA34) did not have such mutations but were resistant to some beta-lactams. Point mutations in *ampR* (at 114, 182, 283, and 288) can also be responsible for beta-lactam resistance \[[@pone.0204936.ref038]\] and *exoU*+ strain PA34 carried mutations at E114A and G283E. Mutations at G283E and M288R in *ampR* were exclusive to *exoU*+ strains. These mutations were correlated with over-expression of *ampC* and *ampR* in *exoU*+ strains. The precise mechanism by which acquisition of the *exoU* associated genomic island results in these mutations is not known. For resistance of *exoS*+ strains, it is possible that beta-lactam resistance involves other resistance mechanisms, such as the upregulation of efflux systems MexCD-OprJ, MexEF-OprN, and MexXY-OprM, \[[@pone.0204936.ref050]\] and hence requires further study for elucidation.

Possession of *exoU* was also associated with higher MICs to fluoroquinolones compared to possession of *exoS*, and this has been shown in previous studies \[[@pone.0204936.ref005], [@pone.0204936.ref010], [@pone.0204936.ref045], [@pone.0204936.ref051]--[@pone.0204936.ref053]\]. Mutations in the QRDRs of target genes topoisomerase II (*gryA* and *gyrB*) and topoisomerase IV (*parC* and *parE*) have been previously shown to increase fluoroquinolone resistance in *P*. *aeruginosa* \[[@pone.0204936.ref054], [@pone.0204936.ref055]\]. Here, it was also observed that fluoroquinolone resistance in *exoU* strains was correlated with a combination of mutations in *gyrA* and *parC*. Sequence analysis indicated that six out of eight *exoU* strains had at least one mutation in either *gyrA* (T83I) or *parC* (S87L). Consistent with other studies, \[[@pone.0204936.ref054], [@pone.0204936.ref056]\] such mutations were responsible for very high MICs to fluoroquinolones. This suggests the possibility that more virulent strains of *P*. *aeruginosa* that have the *exoU* gene may evolve in the clinical environment where high concentrations of fluoroquinolones are used for treatment; for example, in eye infections \[[@pone.0204936.ref057], [@pone.0204936.ref058]\]. The conditions that favour selection of *exoU*+ strains might result in increased resistance to other antibiotics. In addition, this study also detected several mutations in QRDRs in the *exoS*+ population. Mutations at position E468D of *gyrB* and A473V of *parE* were associated with increase MICs to all tested fluoroquinolones. Such mutations have been previously associated with fluoroquinolone resistance *P*. *aeruginosa* \[[@pone.0204936.ref059], [@pone.0204936.ref060]\]. It appears that different types of mutations in QRDRs evolved in the [*exoU*]{.ul}+ and *exoS*+ strains.

An *exoS*+ strain (PA55) was resistant to all beta lactams except aztreonam but no mutations were observed in the studied genes and expression of genes did not correlate with phenotypic resistance. Furthermore, an *exoU*+ strain (PA82) did not have any mutations in QRDRs but was resistant to ciprofloxacin and levofloxacin. However, mutations in V126E the *mexR* of PA82 has been associated with resistance to fluoroquinolone \[[@pone.0204936.ref026], [@pone.0204936.ref061]\]. The evidence from the current study suggests that mutations A110T (PA34) and K76Q (PA175) in *mexR* may confer susceptibility to ceftazidime even in presence of the V126E mutation. This needs to be confirmed by further study.

In addition, we observed a link between the *exoU* and the origin of the strains in India because only one Australian strain (PA175) possessed the *exoU* gene and the resistance rate was higher in the cohort of Indian strains. However, it should be noted that the possession of *exoU* is highly correlated with antibiotic resistance in *P*. *aeruginosa* regardless of source and geographical site of isolation \[[@pone.0204936.ref005], [@pone.0204936.ref009], [@pone.0204936.ref010], [@pone.0204936.ref013], [@pone.0204936.ref045]\]. *ExoU*+ strains may have an evolutionary advantage by having the potential to be both more resistant and more virulent. This is supported by a study that showed higher prevalence of the *exoU* in isolates collected from the hospital environment \[[@pone.0204936.ref062]\]. A correlation between the geographic origin and the *exoU* carriage was observed in this study potentially due to the relatively unregulated use of antibiotics in India compared to Australia \[[@pone.0204936.ref063]\]. However, these observations require confirmation with a larger sample size that should include isolates from various sources and a study of associated epidemiological data.

In conclusion, *exoU* carrying strains, which are common in ocular isolates, showed different antibiotic resistance pattern from isolates with *exoS* genotype. The *exoS*+ strains may be protected from the action of antibiotics due to their ability to cause mammalian cells to ingest them (so-called invasive strains). Their residence inside mammalian cells may offer protection from antibiotics and so diminish selection pressure to convert to antibiotic resistance. The *exoU*+ strains had more mutations in drug resistance determining genes (*gyrA*, *parC*, *mexR*, *ampC* and *ampR*), which was likely to be the cause of higher antibiotic resistance in *exoU*+ strains. Differences in mutational rate in two different virulent genotypes indicate more virulent strains can favourably be evolved in the antibiotic rich environment. Therefore, understanding of both virulence traits and antibiotic resistance is essential for more effective prevention of antibiotic resistance.
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